放射性核素标记[Tyr3]octreotide的体外毒性作用  

Cytotoxicity of[Tyr3] octreotide labeled by radionuclide in vitro

作　　者：周颖明[1,2] 卢霞[2] 王荣福[2] 闫平[2] 张一帆[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院眼科,上海200025 [2]北京大学第一医院核医学科,北京100034

出　　处：《中国医学影像技术》2011年第7期1344-1347,共4页Chinese Journal of Medical Imaging Technology

基　　金：上海市重点学科建设项目(S30205);上海市科委自然科学基金(08ZR1414500);国家重点基础研究发展计划(973计划)项目(2006CB705705);北京大学985Ⅱ期基金(985-2-056)

摘　　要：目的观察放射性核素[131I]标记的奥曲肽(131I-TOC)对Graves病病理生理过程中不同细胞的毒性作用。方法以相同浓度131I-TOC处理增殖期和静止期细胞以及不同性质细胞后,观察131I-TOC的毒性作用;以不同放射剂量的131I-TOC处理活化的成纤维细胞后检测细胞毒性。结果 131I-TOC对增殖期细胞以及活化的成纤维细胞有明显毒性作用;随着剂量增加,细胞毒性增强。结论 131I-TOC有望成为治疗Graves病的新方法。Objective To observe the cytotoxicity of 131I-[Tyr3]octreotide（131I-TOC） to cells involved in the process of Graves ophthalmopathy.Methods 131I-TOC was added to cells in different growth cycle and different cells to assess the toxicity of 131I-TOC to cells.Then the separate dosage of 131I-TOC was cocultured with fibroblast NIH3T3 and the cytotoxicity was measured.Results 131I-TOC had significant cytotoxicity to active fibroblast cells and proliferating cells.Its cytotoxicity was enhanced with increased dosage.Conclusion 131I-TOC might become an effective novel therapy of Graves ophthalmopathy.

关 键 词：格雷夫斯眼病 细胞毒性 免疫 碘同位素 

分 类 号：R817.4[医药卫生—影像医学与核医学] R318[医药卫生—放射医学]